ES2960207T3 - Combinación de dosis fijas de liberación inmediata de memantina y donepezilo - Google Patents

Combinación de dosis fijas de liberación inmediata de memantina y donepezilo Download PDF

Info

Publication number: ES2960207T3
Authority: ES; Spain
Prior art keywords: weight; memantine; composition; donepezil; pharmaceutically acceptable
Prior art date: 2019-05-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES20732664T

Other languages

English (en)

Spanish (es)

Inventor

Machuco Estevens Maria Catarina Oliveira

Marques Da Costa Ricardo Manuel Silva

Serra João Pedro Silva

Filipe Augusto Eugénio Pardal

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Tecnimede Sociedade Tecnico Medicinal SA

Original Assignee

Tecnimede Sociedade Tecnico Medicinal SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-05-31

Filing date

2020-05-29

Publication date

2024-03-01

2020-05-29 Application filed by Tecnimede Sociedade Tecnico Medicinal SA filed Critical Tecnimede Sociedade Tecnico Medicinal SA

2020-05-29 Priority claimed from PCT/IB2020/055137 external-priority patent/WO2020240505A1/en

2024-03-01 Application granted granted Critical

2024-03-01 Publication of ES2960207T3 publication Critical patent/ES2960207T3/es

Status Active legal-status Critical Current

2040-05-29 Anticipated expiration legal-status Critical

Links

ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 title claims abstract description 109
229960004640 memantine Drugs 0.000 title claims abstract description 58
229960003530 donepezil Drugs 0.000 title claims abstract description 49
229940000425 combination drug Drugs 0.000 title claims abstract description 26
239000012729 immediate-release (IR) formulation Substances 0.000 title claims abstract description 26
BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 title abstract description 53
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 44
208000024827 Alzheimer disease Diseases 0.000 claims abstract description 11
239000000203 mixture Substances 0.000 claims description 99
239000008101 lactose Substances 0.000 claims description 25
LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 claims description 23
239000000546 pharmaceutical excipient Substances 0.000 claims description 21
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 20
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 20
229930195725 Mannitol Natural products 0.000 claims description 20
239000008187 granular material Substances 0.000 claims description 20
239000000594 mannitol Substances 0.000 claims description 20
235000010355 mannitol Nutrition 0.000 claims description 20
150000003839 salts Chemical class 0.000 claims description 20
239000003085 diluting agent Substances 0.000 claims description 19
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 18
239000008108 microcrystalline cellulose Substances 0.000 claims description 18
229940016286 microcrystalline cellulose Drugs 0.000 claims description 18
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 18
238000000034 method Methods 0.000 claims description 15
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 14
239000011230 binding agent Substances 0.000 claims description 14
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 14
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 14
239000000314 lubricant Substances 0.000 claims description 14
239000007884 disintegrant Substances 0.000 claims description 13
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 12
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 11
229920002785 Croscarmellose sodium Polymers 0.000 claims description 10
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
239000004480 active ingredient Substances 0.000 claims description 8
XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 claims description 8
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 7
229960003135 donepezil hydrochloride Drugs 0.000 claims description 7
229960000967 memantine hydrochloride Drugs 0.000 claims description 7
238000005550 wet granulation Methods 0.000 claims description 7
GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims description 6
229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 6
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
229920002472 Starch Polymers 0.000 claims description 6
235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 6
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
239000008107 starch Substances 0.000 claims description 6
235000019698 starch Nutrition 0.000 claims description 6
229940032147 starch Drugs 0.000 claims description 6
235000019359 magnesium stearate Nutrition 0.000 claims description 5
235000000346 sugar Nutrition 0.000 claims description 5
150000008163 sugars Chemical class 0.000 claims description 5
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
229960005168 croscarmellose Drugs 0.000 claims description 4
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 4
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
238000002560 therapeutic procedure Methods 0.000 claims description 4
239000000811 xylitol Substances 0.000 claims description 4
235000010447 xylitol Nutrition 0.000 claims description 4
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
229960002675 xylitol Drugs 0.000 claims description 4
SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
239000004375 Dextrin Substances 0.000 claims description 3
229920001353 Dextrin Polymers 0.000 claims description 3
239000001856 Ethyl cellulose Substances 0.000 claims description 3
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
229920002774 Maltodextrin Polymers 0.000 claims description 3
239000005913 Maltodextrin Substances 0.000 claims description 3
229920000881 Modified starch Polymers 0.000 claims description 3
239000002202 Polyethylene glycol Substances 0.000 claims description 3
235000021355 Stearic acid Nutrition 0.000 claims description 3
RVNPCPLQENGXEO-UHFFFAOYSA-N [Na].CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO Chemical compound [Na].CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO RVNPCPLQENGXEO-UHFFFAOYSA-N 0.000 claims description 3
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 3
239000008116 calcium stearate Substances 0.000 claims description 3
235000013539 calcium stearate Nutrition 0.000 claims description 3
239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
229950008138 carmellose Drugs 0.000 claims description 3
229920001577 copolymer Polymers 0.000 claims description 3
229920001531 copovidone Polymers 0.000 claims description 3
229960000913 crospovidone Drugs 0.000 claims description 3
235000019425 dextrin Nutrition 0.000 claims description 3
235000019325 ethyl cellulose Nutrition 0.000 claims description 3
229920001249 ethyl cellulose Polymers 0.000 claims description 3
235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
239000000905 isomalt Substances 0.000 claims description 3
235000010439 isomalt Nutrition 0.000 claims description 3
HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 3
239000000832 lactitol Substances 0.000 claims description 3
235000010448 lactitol Nutrition 0.000 claims description 3
VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 3
229960003451 lactitol Drugs 0.000 claims description 3
229940035034 maltodextrin Drugs 0.000 claims description 3
229920000609 methyl cellulose Polymers 0.000 claims description 3
239000001923 methylcellulose Substances 0.000 claims description 3
235000010981 methylcellulose Nutrition 0.000 claims description 3
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
229920001223 polyethylene glycol Polymers 0.000 claims description 3
229920000193 polymethacrylate Polymers 0.000 claims description 3
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 3
229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 3
229940069328 povidone Drugs 0.000 claims description 3
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 3
239000008109 sodium starch glycolate Substances 0.000 claims description 3
229920003109 sodium starch glycolate Polymers 0.000 claims description 3
229940079832 sodium starch glycolate Drugs 0.000 claims description 3
239000000600 sorbitol Substances 0.000 claims description 3
229960002920 sorbitol Drugs 0.000 claims description 3
235000010356 sorbitol Nutrition 0.000 claims description 3
239000008117 stearic acid Substances 0.000 claims description 3
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
229940072056 alginate Drugs 0.000 claims description 2
235000010443 alginic acid Nutrition 0.000 claims description 2
229920000615 alginic acid Polymers 0.000 claims description 2
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
239000011734 sodium Substances 0.000 claims description 2
229910052708 sodium Inorganic materials 0.000 claims description 2
229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
239000008186 active pharmaceutical agent Substances 0.000 abstract description 7
239000003826 tablet Substances 0.000 description 28
229960001375 lactose Drugs 0.000 description 23
239000000047 product Substances 0.000 description 22
238000004090 dissolution Methods 0.000 description 19
229940120402 donepezil and memantine Drugs 0.000 description 19
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 17
238000009472 formulation Methods 0.000 description 13
229940039856 aricept Drugs 0.000 description 11
238000012360 testing method Methods 0.000 description 8
238000002156 mixing Methods 0.000 description 6
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 5
229960001021 lactose monohydrate Drugs 0.000 description 5
230000036470 plasma concentration Effects 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
229920002261 Corn starch Polymers 0.000 description 4
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 4
239000000544 cholinesterase inhibitor Substances 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
239000008120 corn starch Substances 0.000 description 4
238000007922 dissolution test Methods 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
239000012085 test solution Substances 0.000 description 4
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
238000013459 approach Methods 0.000 description 3
239000002775 capsule Substances 0.000 description 3
229960001681 croscarmellose sodium Drugs 0.000 description 3
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
238000013461 design Methods 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000002050 international nonproprietary name Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229960001855 mannitol Drugs 0.000 description 3
239000002609 medium Substances 0.000 description 3
238000011160 research Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000005434 MCC/mannitol excipient Substances 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000005056 compaction Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
239000012535 impurity Substances 0.000 description 2
239000008203 oral pharmaceutical composition Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000000634 powder X-ray diffraction Methods 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
238000007873 sieving Methods 0.000 description 2
238000003860 storage Methods 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
MCRNHLQVPJEMSQ-UHFFFAOYSA-N C(C=CC(=O)O)(=O)O.C(CCCCCCCCCCCCCCCCC)[Na] Chemical compound C(C=CC(=O)O)(=O)O.C(CCCCCCCCCCCCCCCCC)[Na] MCRNHLQVPJEMSQ-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
239000006189 buccal tablet Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
230000007370 cognitive improvement Effects 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
239000013066 combination product Substances 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical class NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 1
239000007950 delayed release tablet Substances 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000012738 dissolution medium Substances 0.000 description 1
239000007938 effervescent tablet Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
229960003980 galantamine Drugs 0.000 description 1
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000009478 high shear granulation Methods 0.000 description 1
229940071676 hydroxypropylcellulose Drugs 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
239000000845 maltitol Substances 0.000 description 1
235000010449 maltitol Nutrition 0.000 description 1
VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
229940035436 maltitol Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
OGZQTTHDGQBLBT-UHFFFAOYSA-N neramexane Chemical compound CC1(C)CC(C)(C)CC(C)(N)C1 OGZQTTHDGQBLBT-UHFFFAOYSA-N 0.000 description 1
229950004543 neramexane Drugs 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
229940100692 oral suspension Drugs 0.000 description 1
239000006191 orally-disintegrating tablet Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
238000012545 processing Methods 0.000 description 1
229960004136 rivastigmine Drugs 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000003068 static effect Effects 0.000 description 1
239000006190 sub-lingual tablet Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
229960001685 tacrine Drugs 0.000 description 1
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000001238 wet grinding Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Hospice & Palliative Care (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

ES20732664T 2019-05-31 2020-05-29 Combinación de dosis fijas de liberación inmediata de memantina y donepezilo Active ES2960207T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PT2019115557		2019-05-31
PCT/IB2020/055137 WO2020240505A1 (en)	2019-05-31	2020-05-29	Immediate release fixed-dose combination of memantine and donepezil

Publications (1)

Publication Number	Publication Date
ES2960207T3 true ES2960207T3 (es)	2024-03-01

Family

ID=88650785

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES20732664T Active ES2960207T3 (es)	2019-05-31	2020-05-29	Combinación de dosis fijas de liberación inmediata de memantina y donepezilo

Country Status (7)

Country	Link
ES (1)	ES2960207T3 (pl)
HU (1)	HUE063622T2 (pl)
LT (1)	LT3843702T (pl)
MA (1)	MA53513B1 (pl)
PL (1)	PL3843702T4 (pl)
RS (1)	RS64694B1 (pl)
SM (1)	SMT202300336T1 (pl)

2020
- 2020-05-29 ES ES20732664T patent/ES2960207T3/es active Active
- 2020-05-29 SM SM20230336T patent/SMT202300336T1/it unknown
- 2020-05-29 RS RS20230893A patent/RS64694B1/sr unknown
- 2020-05-29 MA MA53513A patent/MA53513B1/fr unknown
- 2020-05-29 PL PL20732664.6T patent/PL3843702T4/pl unknown
- 2020-05-29 LT LTEPPCT/IB2020/055137T patent/LT3843702T/lt unknown
- 2020-05-29 HU HUE20732664A patent/HUE063622T2/hu unknown

Also Published As

Publication number	Publication date
MA53513B1 (fr)	2023-10-31
HUE063622T2 (hu)	2024-01-28
SMT202300336T1 (it)	2023-11-13
PL3843702T3 (pl)	2024-04-08
RS64694B1 (sr)	2023-11-30
LT3843702T (lt)	2023-11-10
PL3843702T4 (pl)	2024-04-08
MA53513A (fr)	2021-09-08

Publication	Publication Date	Title
US11911509B2 (en)	2024-02-27	Pharmaceutical composition comprising Lenvatinib mesylate
ES2617522T3 (es)	2017-06-19	Procedimiento de granulación en seco para fabricar composiciones de comprimidos de metformina y composiciones de los mismos
ES2951547T3 (es)	2023-10-23	Composiciones farmacéuticas que comprenden nilotinib
ES2370943T3 (es)	2011-12-23	Composiciones farmacéuticas estabilizadas que comprenden fesoterodina.
US9545402B2 (en)	2017-01-17	Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-y1)-1H-benzimidazol-2-y1]-1H-quinolin-2-one lactate monohydrate
ES2988678T3 (es)	2024-11-21	Un comprimido que comprende un derivado de metoxiurea y partículas de manitol
JP4707073B2 (ja)	2011-06-22	アトルバスタチン経口投与用粒子状医薬組成物
SK19232001A3 (sk)	2002-06-04	Farmaceutický preparát s levodopou /karbidopou/ entacapónom
JP2012144568A (ja)	2012-08-02	抗痴呆薬の安定化方法
KR20250076516A (ko)	2025-05-29	포말리도마이드의 경구용 정제 조성물 및 이의 제조 방법
US8951504B2 (en)	2015-02-10	(trimethoxyphenylamino) pyrimidinyl formulations
EP3860606B1 (en)	2023-11-08	Pharmaceutical composition comprising lenvatinib esylate or tosylate
US20170231969A1 (en)	2017-08-17	Pharmaceutical Compositions of Edoxaban
TWI418370B (zh)	2013-12-11	溶出安定性製劑
US20140343076A1 (en)	2014-11-20	Pharmaceutical compositions of lurasidone
ES2960207T3 (es)	2024-03-01	Combinación de dosis fijas de liberación inmediata de memantina y donepezilo
JP5900702B2 (ja)	2016-04-06	経口投与用医薬組成物
EP3843702B1 (en)	2023-07-05	Immediate release fixed-dose combination of memantine and donepezil
JP6116847B2 (ja)	2017-04-19	シクロデキストリンとの混合体を含有する錠剤
EP4491175A1 (en)	2025-01-15	A solid oral composition of ruxolitinib
JP2019014700A (ja)	2019-01-31	エゼチミブ含有口腔内崩壊錠及びその製造方法
WO2013137441A1 (ja)	2013-09-19	経口医薬組成物
HK1185801A (en)	2014-02-28	Oral pharmaceutical composition